Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Argatroban

FDA-approved product (injectable, injection), marketed as Argatroban, Argatroban In 0.9% Sodium Chloride, Argatroban In Dextrose and 1 more.

Registered studies
38
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Argatroban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Recurrent thrombophlebitis
  • Thrombocytopenia
  • Thrombotic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct thrombin inhibitors
FDA pharmacologic class
Anti-coagulant; Direct Thrombin Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

38registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Argatroban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Argatroban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Argatroban Plus R-tPA for Acute Ischemic Stroke

    NCT03740958 · start 2018-12-21

    Registered record
    Registry ID
    NCT03740958
    Conditions
    Stroke
    Interventions
    rt-PA; Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-12-21
    Completion
    2022-01-30
    Enrolment
    808

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    Interventionrt-PA; Argatroban
    PhasePhase 4
    Registry statusCompleted

  • Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）

    NCT03506009 · start 2018-07-11

    Registered record
    Registry ID
    NCT03506009
    Conditions
    Argatroban, Rt-PA
    Interventions
    Argatroban combined with rt-PA; rt-PA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-07-11
    Completion
    2018-11-13
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArgatroban, Rt-PA
    InterventionArgatroban combined with rt-PA; rt-PA
    PhasePhase 4
    Registry statusTerminated

  • Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke

    NCT03552354 · start 2017-10-25

    Registered record
    Registry ID
    NCT03552354
    Conditions
    Stroke, Ischemic
    Interventions
    Argatroban plus dual antiplatelet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-25
    Completion
    2019-01-08
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke, Ischemic
    InterventionArgatroban plus dual antiplatelet
    PhasePhase 4
    Registry statusCompleted

  • Safety of Argatroban Infusion in Conduction Disturbances

    NCT05740371 · start 2017-04-18

    Registered record
    Registry ID
    NCT05740371
    Conditions
    Stable Coronary Artery Disease (CAD); Unstable Angina (Troponin Negative)
    Interventions
    Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-18
    Completion
    2021-05-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStable Coronary Artery Disease (CAD); Unstable Angina (Troponin Negative)
    InterventionArgatroban
    PhasePhase 4
    Registry statusCompleted

  • Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

    NCT02935530 · start 2016-01

    Registered record
    Registry ID
    NCT02935530
    Conditions
    Gynecologic Neoplasms; Venous Thromboembolism; Low Molecular Weight Heparin; Argatroban
    Interventions
    s-LMWH; LMWH; Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01
    Completion
    2017-10
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGynecologic Neoplasms; Venous Thromboembolism; Low Molecular Weight Heparin; Argatroban
    Interventions-LMWH; LMWH; Argatroban
    PhasePhase 3
    Registry statusCompleted

  • Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke

    NCT02448069 · start 2015-05

    Registered record
    Registry ID
    NCT02448069
    Conditions
    Stroke; Cerebral Ischemia
    Interventions
    Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05
    Completion
    2016-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Cerebral Ischemia
    InterventionArgatroban
    PhasePhase 2
    Registry statusCompleted

  • Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia

    NCT01911624 · start 2013-01

    Registered record
    Registry ID
    NCT01911624
    Conditions
    Staphylococcus Aureus Bacteraemia
    Interventions
    direct thrombin inhibition; enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-01
    Completion
    2016-07
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteraemia
    Interventiondirect thrombin inhibition; enoxaparin
    PhasePhase 2
    Registry statusCompleted

  • Argatroban in Critically Ill Patients With Heparin Resistance

    NCT01734252 · start 2012-07-29

    Registered record
    Registry ID
    NCT01734252
    Conditions
    Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance
    Interventions
    Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07-29
    Completion
    2016-04-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAchievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance
    InterventionArgatroban
    PhasePhase 2
    Registry statusCompleted

  • Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

    NCT01464788 · start 2011-10

    Registered record
    Registry ID
    NCT01464788
    Conditions
    Ischemic Stroke
    Interventions
    Low Dose Argatroban; High Dose Argatroban; rt-PA (alteplase)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-10
    Completion
    2015-06-11
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke
    InterventionLow Dose Argatroban; High Dose Argatroban; rt-PA (alteplase)
    PhasePhase 2
    Registry statusTerminated

  • Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

    NCT01246011 · start 2010-11

    Registered record
    Registry ID
    NCT01246011
    Conditions
    Coronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 Antibody
    Interventions
    Argatroban and warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-11
    Completion
    2011-07
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 Antibody
    InterventionArgatroban and warfarin
    PhasePhase 4
    Registry statusTerminated

  • Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting

    NCT01163604 · start 2010-08

    Registered record
    Registry ID
    NCT01163604
    Conditions
    CVD
    Interventions
    Argatroban; non-argatroban treated group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2014-08
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCVD
    InterventionArgatroban; non-argatroban treated group
    PhasePhase 4
    Registry statusCompleted

  • Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting

    NCT01980316 · start 2010-04

    Registered record
    Registry ID
    NCT01980316
    Conditions
    CVD
    Interventions
    Argatroban; non-argatroban treated group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-04
    Completion
    2013-07
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCVD
    InterventionArgatroban; non-argatroban treated group
    PhasePhase 4
    Registry statusCompleted

  • Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

    NCT00861692 · start 2009-04

    Registered record
    Registry ID
    NCT00861692
    Conditions
    Heparin-induced Thrombocytopenia Type II
    Interventions
    argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2011-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-induced Thrombocytopenia Type II
    Interventionargatroban
    PhasePhase 2
    Registry statusCompleted

  • Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

    NCT01304238 · start 2009-02

    Registered record
    Registry ID
    NCT01304238
    Conditions
    Acute HIT II (Heparin-induced Thrombocytopenia Type II)
    Interventions
    lepirudin; danaparoid; argatroban; fondaparinux
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-01
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIT II (Heparin-induced Thrombocytopenia Type II)
    Interventionlepirudin; danaparoid; argatroban; fondaparinux
    PhaseNot recorded
    Registry statusCompleted

  • Argatroban Versus Lepirudin in Critically Ill Patients

    NCT00798525 · start 2009-01

    Registered record
    Registry ID
    NCT00798525
    Conditions
    Heparin Induced Thrombocytopenia (HIT)
    Interventions
    Argatroban; Lepirudin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2009-01
    Completion
    2012-03
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin Induced Thrombocytopenia (HIT)
    InterventionArgatroban; Lepirudin
    PhasePhase 4
    Registry statusTerminated